Back to results
US 2020/0268783 A1Published application
Combination therapy for cancer
AssigneeNuCana plc
InventorHugh Griffith
Life of this patent
Estimating the term…
Abstract
This invention relates to a combination of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate (chemical name: 2′-Deoxy-2′,2′-difluoro-D-cytidine-5′-O-[phenyl (benzoxy-L-alaninyl)] phosphate)(NUC-1031) and a platinum-based anticancer agent selected from carboplatin, oxaliplatin, satraplatin and nedaplatin. The combinations are useful in the treatment of cancer and particularly ovarian cancer.
Claims20
1-27. (canceled)
A method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula 2:
- or a pharmaceutically acceptable salt thereof, in combination with carboplatin.
A pharmaceutical formulation comprising:
- a compound of Formula 2:
- or a pharmaceutically acceptable salt thereof,
- carboplatin, and
- at least one pharmaceutically acceptable excipient.
1 more element
A kit comprising:
- a first formulation comprising a compound of Formula 2:
- or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient;
- a second formulation comprising carboplatin, and at least one pharmaceutically acceptable excipient;
- and
- instructions for administering the first formulation and the second formulation in combination to a subject having cancer.
2 more elements
Dependencies are inferred from the claim text.